Oncologists say thousands of cancer patients are either missing out on medication or being forced to spend large portions of their savings on potentially life-saving treatments because of gaps in the PBS.
The National Oncology Alliance (NOA) is calling on the Pharmaceutical Benefits Advisory Committee (PBAC) to subsidise more rare cancer treatments.
Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.
Shaping the future of cancer control together We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year
Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education
